Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study

scientific article

Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.DIABRES.2009.09.008
P698PubMed publication ID19796836

P50authorMykola KhalangotQ60660190
P2093author name stringMykola Tronko
Victor Kravchenko
Vladimir Kovtun
P2860cites workPrimary care diabetes in Ukraine.Q37218319
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectcirculatory systemQ11068
P304page(s)247-253
P577publication date2009-09-30
P1433published inDiabetes Research and Clinical PracticeQ15750054
P1476titleGlibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study
P478volume86

Reverse relations

cites work (P2860)
Q38374279Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review
Q39565271Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population
Q38364806Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.
Q42738237Comment on: Pantalone et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010;33:1224-1229.
Q38524435Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Q38754132Is gliclazide a sulfonylurea with difference? A review in 2016.
Q44802551Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Q38281461Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Q38248399Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations
Q92432007PATIENTS TREATED WITH INSULIN AND SULPHONYLUREA ARE AT INCREASED MORTALITY RISK AS COMPARED WITH THOSE TREATED WITH INSULIN PLUS METFORMIN
Q37577162Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes
Q46887711Response to Comment on: Pantalone et al. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A Retrospective Analysis. Diabetes Care 2010;33:1224–1229.
Q43901204Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study
Q27022613Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials
Q50562456Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study.
Q37878493Sulfonylureas: do we need to introspect safety again?
Q37913528The future of incretin-based therapy: novel avenues--novel targets
Q33873053The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis
Q37961238Treating diabetes today with gliclazide MR: a matter of numbers
Q37933466Variations in tissue selectivity amongst insulin secretagogues: a systematic review

Search more.